Immix Biopharma, Inc. - Common Stock (IMMX)

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024.

IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024.

IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Immix Biopharma Inc (NASDAQ: IMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T 

These best speculative stocks are the ones to buy in the long term for strong returns on your investment portfolio.

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for relapsed or refractory multiple myel

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.